z-logo
Premium
Transfusion‐associated graft vs. host disease in a patient with high‐grade B‐cell lymphoma. Should cellular products for patients with non‐Hodgkin's lymphoma be irradiated?
Author(s) -
Gelly K. J.,
Kerr R.,
Rawlinson S.,
Norris A.,
Bowen D. T.
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02176.x
Subject(s) - lymphoma , medicine , disease , hodgkin lymphoma , graft versus host disease , blood transfusion , hematology , blood product , gastroenterology , immunology , oncology , surgery
We present the case of a 64‐year‐old man who died from transfusion‐associated graft vs. host disease (TA‐GVHD) having been treated 2 years earlier for a high‐grade, non‐Hodgkin's lymphoma (NHL). We suggest that he was at increased risk of developing TA‐GVHD as a result of the NHL and its subsequent treatment, and propose that patients with NHL should be added to those ‘at risk’ groups who receive irradiated cellular blood components.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here